Every Form 4 that Arcturus Therapeutics Holdings Inc. (ARCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARCT filings page.
Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of stock options as part of his 2026 annual board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share, expiring on June 5, 2036.
According to the footnote, the options vest monthly over one year from the grant date, meaning portions become exercisable each month during that period. This is a compensation-related grant, not an open-market purchase, and leaves Holmes with 15,000 derivative securities reported after the transaction.
Arcturus Therapeutics Holdings Inc. director Peter C. Farrell reported receiving a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.3000 per share and expire on June 5, 2036.
The filing describes this as the 2026 annual grant for his service on the Board of Directors. According to the footnote, the shares underlying the option vest monthly over a one-year period from the grant date. After this grant, Farrell holds options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share.
According to the disclosure, the options vest monthly over a one-year period from the grant date, aligning the director’s compensation with the company’s performance over time. All 15,000 options are shown as held directly following this grant, with an expiration date in 2036.
Arcturus Therapeutics Holdings Inc. director John Markels received a grant of stock options as part of his 2026 annual board compensation. The award covers options to buy 15,000 shares of common stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds stock options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. director Moncef Slaoui received a grant of stock options as part of annual board compensation. The award covers 15,000 options for Common Stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds 15,000 derivative securities directly.
Arcturus Therapeutics Holdings Inc. director Magda Marquet received a grant of stock options covering 15,000 shares of common stock, with an exercise price of $7.30 per share and an expiration date of June 5, 2036. The options vest monthly over one year from the grant date and represent her 2026 annual grant as a member of the company’s Board of Directors.
Arcturus Therapeutics Holdings Inc. reported that director Jing L. Marantz received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.30 per share and expire on June 5, 2036.
According to the disclosure, these options represent Dr. Marantz’s 2026 annual grant for service on the Board of Directors. The shares underlying the option vest monthly over one year from the grant date, and following this award she holds stock options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported that its Chief Financial Officer, Dennis Mulroy, received a grant of employee stock options covering 100,000 shares of common stock. These options have an exercise price of $8.63 per share and expire on May 1, 2036.
The grant was made under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan as part of equity compensation. The underlying shares vest 25% on May 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, encouraging longer-term alignment with shareholders.